Serious drug-induced liver disease secondary to ezetimibe.
作者： José Castellote , Javier Ariza , Rosa Rota , Anna Girbau , Xavier Xiol
DOI: 10.3748/WJG.14.5098
关键词: Anticholesteremic Agents 、 Liver testing 、 Toxic hepatitis 、 Biliary cholesterol 、 Drug 、 Pharmacology 、 Ezetimibe 、 Drug-induced liver disease 、 Liver disease 、 Medicine
摘要: Ezetimibe is the first member of a new family lipid-lowering drugs that inhibits uptake dietary and biliary cholesterol. It was approved by FDA in 2002 for hypercholesterolemia alone or combination with statins. Its use has been spreading over last years. considered safe drug. We report case woman who developed serious hepatocellular drug-induced liver disease after 4 mo therapy 10 mg daily ezetimibe. After withdrawal drug, patient recovered slowly. may produce toxic hepatitis prompt mandatory significant abnormality testing beginning during treatment
researchgate.net 
sci-hub.st 参考文章(10)
M Sabaté, L Ibanez, E Pérez, X Vidal, M Buti, X Xiol, A Mas, C Guarner, M Forné, R Solà, J Castellote, J Rigau, J‐R LAPORTE, None, Risk of acute liver injury associated with the use of drugs: a multicentre population survey Alimentary Pharmacology & Therapeutics. ,vol. 25, pp. 1401- 1409 ,(2007) , 10.1111/J.1365-2036.2007.03338.X
Mark F.J. Stolk, Marco C.J.M. Becx, Karel C. Kuypers, Cees A. Seldenrijk, Severe hepatic side effects of ezetimibe. Clinical Gastroenterology and Hepatology. ,vol. 4, pp. 908- 911 ,(2006) , 10.1016/J.CGH.2006.04.014
Willis C Maddrey, Drug-induced hepatotoxicity: 2005. Journal of Clinical Gastroenterology. ,vol. 39, ,(2005) , 10.1097/01.MCG.0000155548.91524.6E
Charles van Heyningen, Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe Annals of Clinical Biochemistry. ,vol. 42, pp. 402- 404 ,(2005) , 10.1258/0004563054890105
Fernando Civeira, International Panel on Management of Familial Hypercholesterolemia, None, Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia Atherosclerosis. ,vol. 173, pp. 55- 68 ,(2004) , 10.1016/J.ATHEROSCLEROSIS.2003.11.010
Qiang Liu, Hillel Tobias, Lydia M. Petrovic, Drug-induced liver injury associated with ezetimibe therapy. Digestive Diseases and Sciences. ,vol. 52, pp. 602- 605 ,(2007) , 10.1007/S10620-006-9497-2
Cynthia A. Jackevicius, Jack V. Tu, Joseph S. Ross, Dennis T. Ko, Harlan M. Krumholz, Use of ezetimibe in the United States and Canada. The New England Journal of Medicine. ,vol. 358, pp. 1819- 1828 ,(2008) , 10.1056/NEJMSA0801461
Sidharth S. Bhardwaj, Naga Chalasani, Lipid-Lowering Agents That Cause Drug-Induced Hepatotoxicity Clinics in Liver Disease. ,vol. 11, pp. 597- 613 ,(2007) , 10.1016/J.CLD.2007.06.010
Raúl J Andrade, Mercedes Robles, Alejandra Fernández-Castañer, Susana López-Ortega, M Carmen López-Vega, M Isabel Lucena, Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World Journal of Gastroenterology. ,vol. 13, pp. 329- 340 ,(2007) , 10.3748/WJG.V13.I3.329
Thomas C. Li, Mark R. Versland, George Y. Wu, Drug-Induced Hepatotoxicity Diseases of the Liver and Bile Ducts. pp. 163- 190 ,(1998) , 10.1007/978-1-4612-1808-1_13